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Distributions of manganese in diverse human
cancers provide insights into tumour
radioresistance†
Philip A. Doble a and George L. Gabor Miklos *b
Many cancers are variably resistant to radiation treatment: some patients die within months, while others
with the same tumour type and equivalent radiation protocol, survive for years. To determine why some
tumours are radiosensitive, while others return after radiotherapy, requires new non-traditional approaches
to oncology. Herein we used laser ablation-inductively coupled plasma-mass spectrometry (LA-ICP-MS) to
test the hypothesis that Mn functions as a metabolic radioprotector and is an apex predictor of tumour
radioresponsiveness. The genesis of this hypothesis lies in microbial and in vitro chemical systems. We
measured the levels and spatial distributions of Mn in tissue sections of 7 specifically chosen tumour types
with distinct clinically documented radioresponsiveness and patient outcomes, namely testis, lung, brain,
skin, mesothelium, prostate and breast. Mn levels varied nearly 60-fold between individual tumours, from
0.02 mg g1 to 1.15 mg g1. The most radiosensitive cancer type, (testis), had the lowest Mn levels and the
highest patient survival. Tumours at the radioresistant extreme (glioblastomas and melanomas) had the
highest Mn levels and lowest patient survival. A direct association was found between total Mn contents
and their variation, and clinically-inferred radioresponsiveness in each of these 7 tumour types, while no
such association existed with Cu, Zn or Fe. The LA-ICP-MS data provided unique patient-specific 2D maps
of the spatial metallomic heterogeneity of cancer cells and their stroma. These maps have fundamental and
far reaching clinical implications. For the first time, Mn-based tumour data may allow for more precise
radiodosages and improved treatment for the individual patient.
Significance to metallomics
Although more than 60% of cancer patients receive radiation treatment, the underlying biological mechanisms of the widespread radioresistance of many
human tumours remain elusive despite decades of research. Research efforts have largely focussed on the genomics/proteomics-based enzymology of DNA
repair and/or free radical scavenging enzymes such as the superoxide dismutases. Here, we propose the novel hypothesis that tumour radioresistance is
predominantly underpinned by non-enzymatic complexes of manganese with small molecular metabolites. These complexes are pivotal to radioprotection. We
found that the distributions of manganese in tumours from testis, brain, melanoma, prostate, breast, mesothelium and lung were associated with clinically-
inferred radioresistance. No associated were found with other biologically important metals. These findings have very significant implications both for Mn-
based mechanisms of radioresistance and patient treatment. For the first time, it may be possible to personalise radiation treatment to an individual patient by
measuring the level of manganese in their tumour biopsies.
Introduction
Of the four major pillars of current cancer treatment, namely
surgery, chemotherapy, radiation and immunotherapy, it is
ionising radiation treatment that alone or in combination with
these modalities, underpins B40% of all cancer cures. Advances in
radiation treatment have largely been achieved by improvements in
tumour imaging, advanced computation and instrumentation.1
However, even with the most sophisticated technologies, such as
proton beam machines and new brachytherapies, these advances
are now near a ceiling. The molecular focus in radiation treatment
remains on developing gene expression and proteomic assays to
fine tune radiation dosages.2,3 This is proving challenging. No
clinically approved tests have yet revealed where a specific
tumour, independently of cancer type, lies on a radioresistance –
radiosensitive spectrum at its time of biopsy.
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The problem in a nutshell is that with the exception of inherited
radiation-sensitising mutations in a small number of genes,
such as Ataxia Telangiectasia Mutated (ATM), no conventional
radiotherapeutic indicators are tumour type-agnostic. Given this
situation, it is prudent to search for the underlying principles of
radiation tumour biology in a different therapeutic area.4
One area which holds promise for clinical radiotherapeutics
is non-enzymatic metallomics. Here it is known that Mn-complexes
render cells variably resistant to the products of ionising radiation
by scavenging the main reactive oxygen species (ROS), formed after
radiation, namely the superoxide radical O2
, hydrogen peroxide
H2O2 and the hydroxyl radical HO. Since the genesis of this
Mn-complexes/ROS scavenging area is in non-enzymatic in vitro
chemistry, and not in conventional enzymology or genomics,
it has not yet attracted the attention of the clinical radiology
community.
The seminal observation by Gregory and Fridovich5 in 1974,
that a free-living organism lacking detectable superoxide
dismutase activity could efficiently scavenge the superoxide
radical, O2
, opened a new vista into the non-enzymatic
mechanisms of ROS metabolism. This work led to the finding
that the scavenging of O2
 was achieved by having millimolar
concentrations of Mn2+ within the cell and it was this dialyzable
Mn2+ bound to low molecular weight molecules that was the
active non-enzymatic scavenger of O2
.6 Subsequent in vitro
cell-free assays revealed that Mn2+ formed complexes with
organic acids such as malate, pyruvate, propionate, succinate
and lactate, and these Mn2+ complexes were highly active in
scavenging O2
, the most efficient being Mn2+-lactate.7
However, it was not just O2
 that could be non-enzymatically
scavenged by Mn2+ bound to low molecular weight molecules.
In vitro cell free assays revealed the catalase-like activity of Mn2+
in bicarbonate buffer.8 Decomposition of H2O2 occurred via a
Mn2+/amino acid/HCO3
 complex.9 This meant that under
physiological conditions, the size of the amino acid pool became
a critical component of protecting proteins and lipids from oxidative
damage.10 Furthermore, manganous phosphate and manganous
carbonate removed O2
 from solution at rates that were similar to
enzymatic removal by superoxide dismutases.11
The non-enzymatic mechanisms involving ROS scavenging
were clarified in cellular studies, predominantly in microorganisms.
It was found that most cellular Mn2+ existed as complexes with
normal metabolites such as peptides, amino acids, orthopho-
sphates, nucleosides, carbonates and organic acids and their
non-enzymatic activities were the dominant processes by which
radioresistance was attained. The enzymatic activities of super-
oxide dismutase, catalase and glutathione peroxidase were minor
contributors.12–19
We pursued this metabolic area in the context of human
tumours because we reasoned that the fundamental properties
of Mn, with its 5 unpaired electrons in its 3d orbital, and its
conserved chemistry of interactions, should apply to human
cancers. We therefore undertook an analysis of patient samples
from different human tumour types where clinically-inferred
radioresistance had been examined (Table 1), with the aim of
using LA-ICP-MS to determine if measurements of Mn levels in
tumours could be helpful in the radiation treatment of cancer
patients.
We assumed that since 95% of cellular Mn2+ exists as low
molecular weight Mn2+ complexes not bound to enzymes, then
total cellular Mn content in tumours could be a useful initial
assay for examining clinically-inferred radioresistance. We
deemed it likely that total Mn content in tumours would be a
reasonable proxy of Mn2+ in high symmetry complexes, which are
the strongest indicator of radioresistance to date.19 Since the
other key components of Mn2+-complexes, namely the cellular
pools of peptides, nucleosides and free amino acids, are generally
present at millimolar concentrations in normal cells, we assume
that they are in similar concentrations in tumour cell populations.
There is certainly likely to be a large and diverse pool of peptides,
since there is no shortage of dying cells and their autoproteolytic
digests within most solid tumours. The large necrotic areas in many
cancers attest to this consequence.
We hypothesise that: (i) some cells in human tumours will
have accumulated sufficient Mn to be protected from radiation-
induced ROS damage at a given radiation dosage, and (ii) the
differences in Mn levels within a tumour will be visible in 2D
analyses of tissue sections and provide information of clinical
utility to patient treatment.
To test the above inferences on Mn-based radioresistance,
we utilised LA-ICP-MS instrumentation to go directly from standard
human pathological sample material to data analysis, with no
interposed sample manipulation steps. The outputs were 2D maps
that revealed a patient-specific, Mn-based, metallomic cartography
of cancer cells embedded in their supporting stroma. The
metallomic topography of such maps allowed testable inferences
to be drawn on the probabilities of tumour radioresistance and
reoccurrence for that specific tumour.
Experimental
Pathological material: tissue microarrays
Arrays were purchased from US Biomax (www.usbiomax.com)
and contained de-identified patient tumour cores designated as
follows; ME804a, primary and metastatic melanomas; TE802,
testicular seminomas and lymphomas; GL806c, glioblastomas;
LC802a, small cell lung cancers; MS801a, mesotheliomas; BR804a,
Table 1 Clinically-inferred resistance and patient survival after radiation
treatment in different categories of cancers. In current patient protocols,
radiation treatment may be preceded by surgery, chemotherapy, immuno-
therapy and adjuvant drugs, or may be used following these interventions.
We use radioresistant and radiosensitive only as convenient descriptors.









Melanoma Radioresistant Intermediate and variable
Mesothelioma Radioresistant Low
Breast Variably radiosensitive High if tumour is localised
Prostate Variably radiosensitive High if tumour is localised
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breast cancers and breast adjacent tissue; PR806, prostate and
prostate adjacent tissue; and FDA999f, different normal tissues.
H&E stained slides were scanned at Royal College of Pathologists
of Australasia Quality Assurance Programs (RCPAQAP) Pty
Limited, St Leonards NSW 2065, Australia, rcpaqap@rcpaqap.
com.au and images examined via ImageScope software from
Aperio. The analyses of the tissue microarrays were executed
under the University of Technology Sydney ethics approval UTS
HREC 2010-481.
Laser ablation-inductively coupled plasma-mass spectrometry
The elemental images were acquired on an Agilent 7770 ICP-MS
coupled to a New Wave Research NWR193 ArF excimer laser.
The ICP-MS was fitted with ‘s’ lenses to enhance sensitivity.
High purity liquid argon (Ar) was used as the carrier gas and
plasma source, while ultra-high purity (99.999%) hydrogen (H2)
was used as the reaction gas. The LA-ICP-MS system was tuned
on a daily basis and for both standard mode and reaction mode
using NIST 612 Trace Elements in Glass for maximum sensitivity
and to ensure low oxide formation. Low oxide production was
assured by measuring a mass-to-charge ratio (m/z) of 248/232
(representing 232Th16O+/232Th+) and was consistently less than 0.3%.
The instrument was fine-tuned for tissue analysis using matrix-
matched tissue standards with monitored mass/charge ratios (m/z),
55 (Mn), 56 (Fe), 63 (Cu) and 66 (Zn). The ICP-MS dwell times were
set according to the parameters outlined by Lear et al.20 to ensure
the elemental image maintained the dimensions of the specimen.
Operational parameters for ICP-MS
The radio frequency power was 1250 Watts; the cooling gas flow
rate was 15.0 litres per minute; the carrier gas flow rate was
1.2 litres per minute, the torch sample depth was 4 millimetres;
the quadrupole bias was 3.0 Volts; the octopole bias was
6.0 Volts; the dwell time was 62 milliseconds per m/z; extraction
lens 1 was 5.0 Volts; extraction lens 2 was 100.0 Volts and the
hydrogen collision gas was 3.1 milliliters per minute.
Laser ablation of pathological material
A glass microscope slide with an unstained section from a tumour
sample was placed in an ablation chamber and a 35 micrometer
diameter high energy laser beam was focused onto the section and
some of the biological material was vaporised as a result of energy
transfer from the laser beam. Argon gas carried the resulting
particulate matter into the ICP, which at a temperature exceeding
7000 degrees Celsius, but below 10 000 degrees Celsius, atomises
and ionises the particulate matter to its constituent elements. The
use of collision/reaction21 minimised spectral interferences, and
‘‘removed’’ polyatomic ions such as and nitrogen:argon (15N40Ar+)
and oxygen:argon (16O40Ar+) species that would otherwise appear
as 55 and 56 signals, respectively, and incorrectly attributed to
55Mn and 56Fe. In the dynamic reaction cell, interfering polyatomic
ions were converted to a different species at a higher mass : charge
ratio (m/z), and no longer interfered with the target ions. Following
emergence from the reaction cell, the ions were focused into a
quadrupole mass filter where they were separated by their m/z
ratios and detected and quantified.
The immediately adjacent tissue section from the H&E slide
was de-paraffininised to generate a 2D elemental map. The laser
was rastered across a sample from left to right, one track at a time
from top to bottom, where the track was 35 micrometers in
width. Each track was saved as individual comma separated
values (csv) files and combined with an inhouse written python
script into a visual toolkit (vtk) format. These files were processed
into quantified and background corrected images using Para-
view, an open source imaging software package (Kitware Inc. 28
Corporate Drive, Clifton Park, New York, 12065 USA).
Preparation of tissue standards
Matrix matched standards were prepared from chicken breast
tissue removed of any fat or connective material and were
partially homogenised using an OmniTech TH tissue homo-
geniser fitted with a polycarbonate probe (Kelly Scientific,
North Sydney, New South Wales, Australia), and subsequently
spiked with standard Mn, Fe, Cu, and Zn solutions. Solutions
were prepared using high purity (min 99.995%) soluble chloride,
sulfate, or nitrate metal salts (Sigma-Aldrich, Castle Hill, New
South Wales, Australia) dissolved in 1% HNO3 (Choice Analytical,
Thornleigh, New South Wales, Australia) and diluted to con-
centrations of ca. 100 000 micrograms per millilitre and 10 000
micrograms per millilitre. Aliquots of the chicken breast were
then spiked with varying concentrations of each of the elements
and homogenised at low speed for 5 min. Six ca. 250 milligram
aliquots of each homogenised tissue standard were digested in
5 : 1 Seastar Baseline grade HNO3/H2O2 (Choice Analytical) in a
Milestone MLS 1200 closed vessel microwave digester (Kelly
Scientific) and analysed using solution ICP-MS to confirm the
concentration and homogeneity of each element in the tissue
standards. The spiked tissue was frozen and cut into 30 micrometer
sections and placed onto glass microscope slides for analysis.
Calibration and background correction
The prepared matrix-matched tissue standards were used to
construct calibration curves for signal normalisation of analytes
across 6 concentration levels. Each standard was analysed by
LA-ICP-MS under the same parameters as the tissue microarrays
as described earlier. 7 consecutive 10 second raster lines were
acquired for each level of standard from which the average
signal was calculated and plotted against concentration. To aid
simple interpretation of the quantified metallomic images, a
normalisation procedure was used to compare each acquisition,
reported in units of normalised counts per second (npcs). Here,
we divided the slope of the calibration curves to generate a
correction factor that was applied to each of the images to
ensure consistent signal sensitivity throughout the study. The
concentrations of the analytes, slopes, correlation coefficients
and correction factors are detailed in ESI,† Table S1.
Background corrections were performed on 55Mn, 56Fe, 63Cu
and 66Zn by extracting the signal from representative areas of
the image where no tissue was ablated. The median signal
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Results
We measured the levels and distributions of Mn, Cu, Zn and Fe
in 359 formalin-fixed, paraffin-embedded, unstained tissue
sections from tumours of cancer patients and from organs of
healthy individuals. The details are in Materials and methods
and in Hare et al.22
Controls and standards from normal tissues
To provide a foundation for the cancer data, we determined metal
levels and their variations in tissue sections from the liver, brain,
heart muscle, pancreas and spleen of normal individuals. We did
so since there are important gene expression data on metal
transporters that modulate influx and efflux of Mn from the
gastrointestinal tract after dietary ingestion and its release into the
bloodstream.23,24 The amount of Mn available to a tumour, be it at
primary or metastatic sites, will initially be determined by how
much Mn passes through this gateway into the bloodstream.
Laser ablation was carried out on a standard glass slide on
which an unstained section of patient material, derived from a
tissue microarray, had been cut at 5 mm thickness from a
formalin-fixed paraffin-embedded (FFPE) block. Fig. 1(A) shows
an example of a single laser-ablating track in the abscissa (x)
direction on a section of normal liver.
A 6 pixel portion of this 30 pixel single laser track has been
overlaid with the high quality pathological features of an
hematoxylin and eosin (H&E) stained photomicrograph from
the tissue section immediately adjacent to the unstained, laser-
ablated section in Fig. 1(B).
Each pixel in the image represents a voxel of 35  35 
5 mm3. The metallomic data from this single 1 mm track
(of length 30 pixels), were acquired in 7.1 seconds.
By laser ablating tracks in the abscissa (x) direction followed
by sequential contiguous ablation in the ordinate (y) direction,
we generated a Cartesian coordinates system map of quantified
metals for the entire liver sample. The median of all voxels in a
sampled region represented the median Mn, Cu, Zn and Fe
levels of that section for that particular patient. The levels were
normalised and corrected for background by concurrently measured
controls of precisely defined standards and expressed in units of
normalised counts per second (ncps) (Materials and methods and
ESI,† Table S1).
The liver tissue sample in Fig. 1 provided B800 voxels of
biological material for evaluation. We analysed data from this
entire sample and from smaller regions of the 800 voxel spot to
determine the minimum sample size needed to obtain a reliable
estimate of metallomic values. In nearly all cases, sample sizes
of 150 voxels did not deviate from the median of the whole
sample by more than 10%, and usually by less than 5% (ESI,†
Table S2). We used a minimum sample size of 150 voxels,
usually more, for analyses of normal and cancerous samples,
equivalent to sampling between 500 to 1000 cells.
The background-corrected metal contents per voxel in
normalised counts per second (ncps) and their associated
standard deviations (StDev) for a 500 voxel sample from this
healthy liver were; Mn = 16 970 ncps, (StDev 2,820); Cu = 17 660 ncps,
(StDev 11 430); Zn = 45 530 ncps, (StDev 5101) and Fe =
4 471 690 ncps, (StDev 1 207 010). These values can equally be
expressed as mg g1, with which the mass spectrometry community
is familiar. For the above, these values are; Mn = 0.65 mg g1;
Cu = 6.01 mg g1; Zn = 9.79 mg g1 and Fe = 249 mg g1. The
broad audiences for these LA-ICP-MS data include oncologists,
radiologists, pathologists and genome and proteome specialists,
most of whom are more familiar with counts per second
terminology. We have therefore used it as the preferred method
of presentation.
The quantitative Mn levels in five normal tissues/organs,
(liver, cardiac muscle, spleen, pancreas and cerebral cortex), the
variation between them, and the variation between different
healthy patients, are given in ESI,† Table S3.
We now examine patient samples from each of the seven
tumour categories described in Table 1 to evaluate any metallomic
linkages to tumour radioresistance. Extensive patient-centric
information on each of these tumour types is available from the
UpToDate clinical decision support resource for physicians
(https://www.uptodate.com/home).
1. Mn, clinically-inferred radioresistance and patient survival
in cancers of the testis and the brain. Certain cancer types of the
testis (namely, classical seminomas) are clinically accepted as
being exquisitely radiosensitive.25–29 In contrast, advanced
brain cancers such as glioblastoma multiforme are notoriously
radioresistant.30,31 These two tumour types represent extremes
Fig. 1 LA-ICP-MS of a tissue sample from the liver of patient #351, a
healthy 38 year-old male. (A) Laser ablation track across the sample.
(B) High resolution image of a 6 pixel part of the track where each pixel
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of the radiotherapeutic spectrum shown in Table 1 and are a
starting point for asking if Mn-based metabolic systems are
major contributors to the radioresistance of human tumours.
The metallomic data on median Mn levels from tumours of
53 patients with classical testicular seminomas are compared
to data from 26 patients with glioblastomas (Fig. 2(A and B),
respectively), and their overall survival curves are shown in
Fig. 2(C and D), respectively. As we do not have overall survival
data for these 53 classical seminoma patients or for these 26
glioblastoma patients, they have been derived from the US
National Cancer Institute’s Surveillance, Epidemiology and
End Results (SEER) database (http://www.seer.cancer.gov).
The median level of Mn from the tumour of each individual
cancer patient is represented as a separate box in the histograms of
Fig. 2. The 53 classical testicular seminoma patients clustered
around a median Mn tumour level of 1030 ncps per patient, while
the brain patients had a more than 3-fold higher median
Mn tumour level of 3560 ncps, with some patients exceeding
10 000 ncps. The two distributions differed significantly,
(Kolmogorov–Smirnov test, D = 0.83 with a corresponding
P = 0.00). Furthermore, 95% of the classical seminoma patients
had median Mn tumour levels of o2000 ncps, while 81% of the
brain patients had Mn tumour levels of 42000 ncps. There
was a large between-patient variation in the glioblastomas
with a standard deviation of 3760, compared to 410 for the
seminomas.
We found only one study on Mn in glioblastomas using
LA-ICP-MS applied to tissue sections, and it involved three
patients.34 The Mn tumour levels in that study varied 10-fold
between two patients, in line with the large variation that
we observed between tumours of glioblastoma patients. No
information was available on the third patient.
An additional aspect of Mn levels in the tissue sections of
the seminomas and glioblastomas is illustrated in Fig. 3. While
cell densities are approximately comparable between these two
tissue sections, (Fig. 3(B and D)), their median Mn tumour
levels are nearly five-fold different at 1000 ncps and 4760 ncps
for the seminomas and glioblastomas, respectively. Thus, Mn
tumour levels are not, in general, due to cell density differences.
Patient survival. The overall survival data for classical semi-
nomas and glioblastomas are available from three independent
sources and the data from those sources are congruent.
First, the SEER database has overall survival data for cancer
patients irrespective of their treatment modalities. These data
encompass all types of treatment received by patients, such as
surgery, radiation and chemotherapy. Patients with testicular
seminomas have low cancer-specific mortality, with more than
98% of patients still alive after 5 years.32 Patients with glioblastomas
have a high cancer-specific mortality with less than 3% alive
after 5 years33 (Fig. 2(C and D) respectively).
Second, The Pathology Atlas of the Human Cancer
Transcriptome,35 has survival data for testicular cancers and
gliomas irrespective of their treatment modalities, and these
survival curves closely mirror those from the SEER database.
The third data source is from those patients for whom
radiation was the sole or major treatment. These data match
those from the above two sources. Radiation-treated seminoma
patients have cure rates exceeding 95% at 10 years leaving little
doubt of their extreme radiosensitivity.25–28 By contrast, radiation
treatment of tumours of glioblastoma patients barely prolongs
survival, with less than 10% of patients surviving at 3 years, even
after radiation to 90 Gy and adjuvant temozolomide treatment.30,31
The most compelling finding of radioresistance in glioblastomas is
Fig. 2 Median Mn levels in tumour sections from patients with cancers of the testis and of the brain and their survival curves. (A) Mn levels from each
of 53 classical seminoma patients (green boxes); (B) 26 glioblastoma patients (red boxes). Overall survival curves over a 5 year period for patients with
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that tumours reoccur within regions that were given even higher
doses of radiotherapy.
Levels of other metals: Zn. The large differences in the median
Mn tumour levels of patients with classical seminomas or
glioblastomas contrasts markedly with the levels of Zn determined
from the same voxels in the same tumours (Fig. 4).
The 53 classical testicular seminoma patients had a median
Zn tumour level of 8520 ncps per patient, while the brain
patients had a median Zn tumour level of 7740 ncps. The
standard deviations were similar at 3490 and 3520, respectively.
The two distributions did not differ significantly, (Kolmogorov–
Smirnov test, D = 0.20 with a corresponding P = 0.46).
We conclude from the above data that (i), classical testicular
seminoma, a known clinically-inferred very radiosensitive tumour
type with very high patient survival after radiation treatment, has
very low median Mn levels. In contrast, (ii), glioblastoma, which
represents the deadliest of all brain tumour types, and is a known
clinically-inferred very radioresistant tumour type with very low
patient survival, has high median Mn levels. In addition, (iii),
median Zn levels neither track radioresponsiveness nor patient
survival in these two tumour types. The LA-ICP-MS data are
consistent with an involvement of Mn in radioresponsiveness.
2. Mn and clinically-inferred radioresistance in atypical
seminomas. Although most seminomas are radiosensitive,
between 5–15% consist of pathologically distinct subtypes (atypical/
anaplastic) which have some degree of radioresistance. Of the
59 testicular seminomas examined herein, 53 were classical
seminomas described above, while 6 were pathologically atypical,
described below.
The LA-ICP-MS data of the 6 atypicals (red boxes) are shown
in Fig. 5(A, B, C and D), for their Mn, Cu, Zn and Fe levels
respectively. It is striking that all six atypicals had elevated Mn
tumour levels (Fig. 5(B), red boxes) which did not overlap with the
Mn tumour levels of the 53 classical seminomas (Fig. 5(A), green
boxes). Two of these atypicals had median Mn tumour levels that
exceeded 10 000 ncps. By contrast, these same six atypicals had Cu,
Zn and Fe tumour levels that fell within the range of the classical
seminomas for those metals, (Fig. 5(B, C and D) respectively). The
atypicals are thus distinguished by their higher Mn tumour levels,
while their Cu, Zn and Fe levels, with one exception, remain within
the boundaries of the classical seminoma levels for each metal.
Survival data are unavailable for these 6 patients. However,
examination of published data of unrelated patients with atypical
seminomas who did receive radiation treatment, reveal that they
have a reduced survival rate of 50–70% at 10 years.25,28 Atypical
seminomas thus have a degree of clinically-inferred radio-
resistance with some variation between studies.
We conclude from the above data that within the single
cancer category of testicular seminoma, (i), the clinically-inferred
radiosensitive classical seminomas have high patient survival and
low Mn tumour levels, while the clinically-inferred radioresistant
atypical seminomas have far lower patient survival and higher Mn
levels. In contrast, (ii), median Cu, Zn and Fe tumour levels neither
track radioresponsiveness nor patient survival in these two
categories within the same tumour type. It is important to note
that (iii), the primacy of Mn levels as regards clinically-inferred
radioresponsiveness and patient survival, has a strong parallel
in the in vitro data on the irradiation of purified proteins in
solution: certain Mn2+ complexes are radioprotective for ROS
damage, but Cu, Zn and Fe are not.13 The LA-ICP-MS data are
consistent with an involvement of Mn in radioresponsiveness.
3. Mn and clinically-inferred-radioresistance in melanomas.
Melanomas are a pathologically and clinically heterogeneous
group. This extends across all treatments, be they radiotherapy,
Fig. 3 Generic examples of the morphologies of classical seminoma and
glioblastoma. (A and B), low and high-power images from patient #47,
a 55 year-old male with a classical seminoma showing characteristic
collagen streaks throughout the tumour (pink), (A). (C and D), patient
#197, a 40 year-old male with glioblastoma showing characteristic abnormal
blood vessels and areas of necrosis, visible as the large pink area in (C).
Fig. 4 Median Zn levels in tumour sections from (A) each of the 53
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chemotherapy, immunotherapy, or drugs. They are clinically
accepted as being in the radioresistant category since radiation
treatment of melanoma patients is often disappointingly
inefficacious, even though some patients respond well to it.36–38
To determine where melanomas lie on the metallomic and
the radiotherapeutic spectra, we examined tumours of 65 melanoma
patients for their Mn, Cu, Zn and Fe tumour levels.
The metallomic data of the patient samples consisted of 35
primary tumours and 30 metastases from different patients. The
distribution of Mn tumour levels at primary sites was not signifi-
cantly different from that in metastases (Fig. 6) (Kolmogorov/
Smirnov test, D = 0.19, P = 0.56). This allowed the data to be pooled.
The median Mn tumour levels of all 65 patients are shown in
Fig. 7 and they are compared to those of the classical seminoma
patients. The median Mn tumour level in melanomas was
2990 ncps per tumour (StDev 6020) and 31% of patients had
Mn tumour levels below 2000 ncps. The two distributions
differed significantly (Kolmogorov/Smirnov test, D = 0.72, P = 0.00).
Fig. 5 Comparisons of the median Mn, Cu, Zn and Fe tumour levels from
53 patients with classical testicular seminomas (green) and six patients with
atypical/anaplastic seminomas (red). The characteristics of the six atypical
patients are: patient #3, (T1N0M0); patent #5, (T1N0M0); patient #34,
(T4N0M0); patient #52, (T1N0M0); patient #62, (T3N0M0) and patient
#69, (T1N0M0). The TNM staging system is the standard usage: T denotes
the size and extent of the main tumour, N the number of lymph nodes
containing abnormal cells and M the extent of metastasis to distant tissues
or organs.
Fig. 6 Histograms of median Mn tumour levels; (A) from different primary
anatomical sites of melanoma patients #81 through #120, and (B) from
metastatic sites, (nearly all in lymph nodes), of melanoma patients #121
through #158.
Fig. 7 Histograms of median Mn levels in tumours of; (A) all 65 melanoma
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Melanomas have a large between-patient variation in Mn
tumour levels with a standard deviation of 6020 compared to
standard deviations of 410 for classical seminomas and 3760
for glioblastomas.
There are important metallomic and clinical findings within
the heterogeneity of melanomas, a major distinguishing feature
being the melanin content of a tumour. Using both visual H&E
staining and algorithmic criteria of melanin content, we sorted
the 65 melanomas into two groups; 18 tumours with no visible
or very low melanin content (herein designated amelanotic
melanomas) and 47 melanomas with variable to large amounts
of melanin (herein designated pigmented melanomas). Two
representative examples of an amelanotic and a pigmented
tumour are shown in Fig. 8.
The LA-ICP-MS Mn patient data from the 18 amelanotic and
47 pigmented melanomas are shown in Fig. 9.
The median Mn level of amelanotic tumours was 1560 ncps
(StDev 799), while pigmented tumours had a median Mn tumour
level of 3550 ncps (StDev 6740). Furthermore, 67% of the amelanotic
tumours had Mn levels below 2000 ncps, (Fig. 9(A), light orange
boxes), while only 15% of the variably pigmented tumours had
Mn levels below 2000 ncps (Fig. 9(B), red boxes). Individual
areas in some pigmented tumours exceeded 50 000 ncps. The
two distributions differed significantly (Kolmogorov/Smirnov
test, D = 0.45; P = 0.004).
Survival data were unavailable for the patients with amelanotic
and pigmented tumours examined herein. However, examination
of published data from unrelated patients who received radiation
treatment for their metastatic tumours provided insights on
overall survival.39 Melanoma patients with amelanotic metastatic
tumours had a median overall survival of B24 months after
radiotherapy, (Fig. 9(C)), compared to B13 months for patients
with pigmented metastatic tumours (Fig. 9(D)). Patients with
pigmented tumours had shorter overall survival times than those
whose tumours were largely devoid of melanin.
Fig. 8 Tissue sections of amelanotic and pigmented melanomas. (A) An
amelanotic tumour from the forefinger of patient #109, a 54 year-old
male. (B) A melanised melanoma from a lymph node of the neck of patient
#122, a 29 year-old female.
Fig. 9 Median Mn tumour levels in tissue sections of amelanotic and pigmented tumours; (A) 18 patients with amelanotic melanomas (light
orange boxes); (B) 47 patients with pigmented melanomas (red boxes) with varying levels of melanin content; (C) overall survival for patients having
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The presence of melanin in a tumour means that interpretations
of radioresistance in terms of Mn, Cu, Zn and Fe levels are not
straightforward. The reason for this is that melanin chelates
and stores a number of metals, including Mn (Fig. 10).
Fig. 10 reveals the concentrations of melanin in the H&E
stained tissue section (Fig. 10(A)) and in the bioinformatics
generated image (Fig. 10(B)). There is a clear pattern where the
concentration of melanin is the highest. The four panels below
show the concentrations of Mn, Cu, Zn and Fe: the highest
concentrations of each metal readily superimpose on the highest
melanin concentrations.
The patient survival data of Fig. 9 reveal that melanin, and/or its
metallomic contents are radioprotective. However, we have not
been able to deconvolute the mechanistic inputs to cellular radio-
resistance of pigmented melanomas since the radioprotective
outcome is composed of differing contributions.
In one tumour, melanin may have chelated none or very low
amounts of Mn depending on Mn availability in the bloodstream,
and/or the Mn transporter levels within that tumour. In another
pigmented tumour, melanin may have chelated large amounts of
Mn. In addition, the contribution to radioprotection may also
derive solely from Mn complexes and/or from combinations of
the above.
We conclude from the above data that (i), although melanomas
have traditionally been considered as largely radioresistant in the
past, they are now better appreciated as being clinically hetero-
geneous and spanning a wider range of radioresponsiveness. This
clinical heterogeneity is reflected in the heterogeneity of the Mn
data. Furthermore, (ii), irrespective of their location in the body,
and irrespective of whether they are primary tumours or their
metastases to lymph nodes, the melanomas exhibit a large
variance in their median Mn levels. Importantly, (iii), a subset
of melanomas lack detectable melanin pigment, have low Mn
levels, and patients with these metastatic amelanotic tumours have
higher overall survival than patients with metastatic pigmented
melanomas, whose survival is relatively reduced. The LA-ICP-MS
data are consistent with an involvement of Mn and/or melanin
in radioresponsiveness.
4. Mn and clinically-inferred radioresistance in mesotheliomas.
Mesotheliomas are a rare cancer category. We chose them for
LA-ICP-MS analysis since malignant pleural mesotheliomas
have traditionally been considered radiation resistant. This
clinically-inferred radioresistance contrasts with the earlier work
on some newly established cell lines from different patients
which were radiosensitive.40
The current clinical situation of radiation treatment for
mesothelioma patients is a controversial one. Residual gross
disease cannot be eliminated even with high dose radiation, which
is certainly indicative of tumour radioresistance.41,42 However,
there have been some good responses to radiation in selected
patients, which is indicative of radiosensitivity.42 Mesotheliomas
thus lie in an indeterminate clinical zone wherein there is a
traditional view of radioresistance, a more recent view of some
radiosensitivity, and cell line data which show variable radio-
sensitivity. The net result is that there is no consensus on an
optimal palliative radiotherapy regimen, there is variation in
clinical practice worldwide, and there is variation in international
guidelines.
The LA-ICP-MS Mn data from 27 mesothelioma cancer
patients are shown in Fig. 11(A). The median Mn level was
2160 ncps (StDev 2840) and 44% of the mesotheliomas had Mn
levels below 2000 ncps. These mesotheliomas are heterogeneous for
total Mn content.
Patient survival data are unavailable for the 27 mesothelioma
patients examined herein. However, such data are available from
independent sources and the data from those sources are congruent.
Fig. 11(B) shows patient survival data from those who first received
radiation, followed by surgery. This curve differs very little from a
study of two decades ago where 176 patients first underwent surgery,
followed by adjuvant chemotherapy and radiation.43 If the survival
curve is taken as an indicator, then mesotheliomas are heterogenous
for radiation resistance, with tumours varying from radiosensitive to
radioresistant. Indeed, de Perrot et al.,42 conclude that ‘‘Increasing
evidence has supported that mesotheliomas are sensitive to
radiation therapy’’.
Given that mesotheliomas are variable for Mn levels, (and for
their differing clinically-inferred radioresistance), the LA-ICP-MS
Fig. 10 H&E stained tissue section of a melanoma from the left chest wall
of patient #107, (T3N0M0), with its 2D distribution of melanin, together
with the 2D distribution of Mn, Cu, Fe and Zn in corresponding voxels. (A)
H&E stained tissue section; (B) bioinformatics threshold analysis revealing
melanin concentrations in the stained tissue section. The concentrations
of Mn, Cu, Fe and Zn from identical voxels of the tumour tissue section are
shown in the four panels. The colour thresholds for each of the metals in
ncps are approximately; (Mn, 1000–2500 light blue/pale red, 2500–9000,
red). (Cu, 200–1000 light blue/pale red, 1000–2000, red). (Zn, 4000–
6000 light blue/pale red, 16 000–52 000, red). (Fe, 20 000–80 000 light
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data may be useful pointers for deciding which patient are likely
to obtain the most benefit from intention-to-treat or palliative
radiation treatment.
We conclude from the above data that (i), although mesothelio-
mas have traditionally been considered as largely radioresistant,
more recent clinical evidence reveals them to be heterogeneous in
terms of radioresponsiveness and patient survival. This clinical
heterogeneity is reflected in Mn heterogeneity. The LA-ICP-MS data
are consistent with an involvement of Mn in radioresponsiveness.
5. Mn and clinically-inferred radioresistance in small cell
cancers of the lung. Small cell cancers of the lung reveal several
clinical characteristics that highlight the challenges of inter-
preting the outcomes of radiation treatment in terms of tumour
response, anatomical site and patient survival. First, cell lines
of small cell lung tumours have remarkable sensitivity to even
small doses of radiation, so at the tissue culture level, they are
radiosensitive.44 Second, in early (limited stage) tumours, where
the cancer is still confined to the chest in a single tolerable
radiation field, tumour response rates can be as high as 60–80%,
so early stage tumours are definitely radiosensitive in a clinical
context.45
The LA-ICP-MS Mn data from 21 small cell lung samples are
shown in Fig. 12(A). The median Mn level was 1230 ncps (StDev
620) and 86% of the tumours had Mn levels below 2000 ncps.
Patient survival data are unavailable for the 21 patients
examined herein. Since the clinical data are indicative of radio-
sensitivity, patient survival is expected to be high after radiation
treatment. This is not the case: survival is relatively low (Fig. 12(B)).
The reasons for this apparent inconsistency illustrate the variables
involved in understanding tumour trajectories in multi-organ
systems that impinge on patient survival.
First, the patients constituting the survival curve of Fig. 12(B)
were elderly, 470 years of age, and this may be a contributing
factor. Second, cancers of the lung are usually diagnosed late,
because the lung is a soft and compressible organ in a fairly large
cavity and there is adequate space for tumour growth without
impinging on vital functions or giving rise to warning symptoms.
Late detection means that cancer cells have already spread
to other sites such as bone, brain or bone marrow and
these metastatic lesions are usually well advanced, leading to
early death. The early dissemination of small cell lung cells
may be influenced by their short doubling time and high
mitotic index.
We conclude from the above data that small cell lung
tumours are initially radiosensitive and are low in Mn. However,
their subsequent aggressive cell division properties and rapid
metastatic spread throughout the lung, decouple this initial
radiosensitivity from expected patient survival after radiation
treatment. The LA-ICP-MS data are consistent with an involvement
of Mn in radioresponsiveness.
6. Mn and clinically-inferred radioresistance in early stage
prostate and breast cancers. Prostate and breast cancers have
several commonalities including being two of the major secretory
organs of the body. The most striking is that in both cancer types
the majority of patients have high overall survival when tumours
are detected early, while a minority of patients have aggressive
Fig. 11 (A) Median Mn levels in tissue sections from tumours of mesothelioma patients. (B) Overall survival of 90 consecutive treatment-naı̈ve patients
receiving radiotherapy followed by surgery (estimated from reference42).
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cancers that respond poorly to any treatment modality and result
in a low survival rate.47
Prostate cancer data. The LA-ICP-MS Mn data of the 16
prostate and 26 breast cancer patient samples are shown in
Fig. 13(A and B) together with the 5 year survival data in panels
(C and D).
Of the prostate cancer patients, 56% have tumours with
median Mn level o2000 ncps. Patient survival data are unavailable
for the 16 patients examined herein, but the results of the latest
ProtecT clinical trial reveal that 99% of early stage prostate cancer
patients who received radiotherapy as a single treatment were alive
at 5 years.48 Prostate cancer-specific mortality at 5 years is thus
extremely low at B1%, (Fig. 13(C)). Previous clinical trials in this
area that claimed much higher mortality rates have been shown to
be compromised at multiple levels.50,51
The single outlier prostate cancer patient shown in Fig. 13(A)
is informative in terms of his Gleason scores and grades relative
to Mn levels in the remaining 15 patients. This cancer patient
(#269) has a median Mn tumour level of 14 020 ncps and a
Gleason score of 8. By contrast, prostate cancer patient #259
has a Mn tumour level of only 890 ncps, a 15-fold difference, yet
he too has a Gleason score of 8 with the same tumour grade
T4N1M1c. This finding is consistent with the data from our
other tumour types, namely that Mn levels do not track tumour
grade to any appreciable extent.
Breast cancer data. Of the breast cancer patients, none of
whom had distant metastases, 57% had median Mn tumour levels
below 2000 ncps and we infer significant radiation sensitivity.
Patient survival data are unavailable for the 26 patients examined
herein. However, the latest data from the National Cancer
Database NCDB, (a joint project of the American College of
Surgeons and the American Cancer Society), reveal that the
5 year overall survival was B93% for those patients with high
risk early stage breast cancer who underwent whole breast
radiotherapy after breast conserving and adjuvant chemotherapy
(Fig. 13(D)).49 The benefits of irradiating the whole breast are not
in dispute, as reoccurrence of the tumour is reduced by B50%
and the death rate by B16%.52,53
The single outlier breast cancer patient in Fig. 13(C) was
informative in terms of her tumour grade relative to Mn levels in
the other 20 patients. This cancer patient (#301) had a median Mn
level of 11 620 ncps and a tumour grade of T2N1M0. By contrast,
patient #293, had a Mn level of 1540 ncps, an B8-fold difference in
Mn level, yet with a similar grade of T2N0M0. This outlier is
pathologically unremarkable compared to the remaining breast
cancer patients, and again, Mn levels do not track tumour grade. It
is likely that the underlying generator of response to radiation is
not predominantly within the traditional histopathology and
immunohistochemistry areas. In this context, as revealed by the
Swedish Breast Cancer Group 91 randomised clinical trial,54 the
literature on breast cancer subtypes is discordant on the effects of
radiation treatment.
We conclude from the above data that (i), localized cancers
of the prostate and early stage cancers of the breast, both with
high patient survival after radiation treatment, have relatively
low Mn levels. In addition, (ii), it is also clear that the under-
lying Mn-based properties of these two tumour types may be
clinically more informative as regards radiation treatment than
some currently utilised pathological parameters.
7. Mn heterogeneity within tumours. We have examined
the heterogeneity within tissue sections of all seven tumour
types, since we hypothesise that regions of high Mn content in
Fig. 13 Median Mn tumour levels in tissue sections from prostate and breast cancer patients. (A) 16 prostate cancer patients (pale blue); (B) 26 breast
cancer patients. (C) Overall survival curve for prostate cancer patients over a 5 year period (estimated from reference48); (D) overall survival curve for
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a tumour will survive radiotherapy and the tumour will likely
progress, leading to reoccurrence after radiation treatment.
Heterogeneity in breast cancers. We illustrate this variation
with patient #324, a 48 year-old female with invasive ductal
carcinoma (Fig. 14(A)). This example highlights a number of
challenges that cannot be avoided in interpreting patient data
at any level, be they ’omic or non-enzymatic.
The various cell types in this tissue section are highlighted
in the contrast-enhanced image of Fig. 14(B) and the H&E
stained high-power microscopic image (Fig. 14(C)).
Five lymphatic vessels, c1 through c5, have been invaded by
cancer cells. While the invasive cells in c1 through c4 all have
median Mn levels less than 3000 ncps, the cancer cells in c5
have 8600 ncps. The invasive cells in all five lymphatic vessels
appear morphologically similar, yet only the c5 group has high
Mn and is potentially a radioresistant metastatic cell lineage.
The immune cell region has a median Mn level of 2720 ncps,
the normal breast region has a median of 3160 ncps and the
adipocyte population has a median near 1000 ncps. The entire
tissue sample has a median Mn level of 1740 ncps. Clearly,
‘‘grinding up/homogenizing’’ such a heterogeneous tumour
sample for metallomic or ’omic analyses results in the pooling
of the metallomic and molecular contents of at least eight
different cell populations (not including other stromal cells)
and completely obliterates the critical spatial information
which is the basis for providing accurate estimates of clinically
important parameters. Once 2D information is destroyed, there
is no platform for deciding which parts of a tumour are likely to
progress after radiation treatment, nor for determining the
probability of tumour reoccurrence.
The heterogeneity seen here at the metallomic level has
parallels with that found in different regions of primary ductal
carcinomas analyzed for genome-wide copy number variation
by comparative genomic hybridization.55 Critically, neither the
status of ER, PR and Her2, nor tumour grade in that study,
correlated with genomic heterogeneity. Furthermore, single
cell sequencing revealed that different parts of the same
tumour had massive amplifications of particular genes, such
as a 50-fold amplification of KRAS. Single chromosomal regions
also had 30 different copy number variations, deletions and
amplifications. Aneuploidy and segmental aneuploidy are common
occurrences,56 not only in tumours of the breast, but in virtually
all solid tumours.
Heterogeneity in melanomas. The second example of intra-
tumoural variation is illustrated by melanoma patient #112, a
48 year-old male with a malignant melanoma of the neck.
Fig. 15 (A) illustrates the H&E stained tissue section that
consists of both pigmented cells, extracellular melanin plus a
pale staining cellular region in the top right quadrant that is
Fig. 14 (A) H&E stained section of a ductal carcinoma of the breast
(T2N0M0) from patient #324 illustrating the morphological heterogeneity
in a single tumour. (B) Contrast enhanced image of panel A to clearly show
the various contributing cell types; (c1 through c5), 5 lymphatic vessels
which have been invaded by cancer cells; adipocytes, large white spheres;
normal, an area of normal ducts; immune, a concentration of invading
immune cells. (C) Higher power of a track through lymphatic vessel c5, the
immune cell group, adipocytes, stroma and normal ducts.
Fig. 15 (A) H&E stained section from patient #112 of a cutaneous melanoma
of the neck (T2aN0M0) showing a major region of pigmentation (lower half)
and a lightly staining region low in melanin (upper right quadrant); (B) 2D
bioinformatics-generated image of melanin levels in individual voxels of the
melanoma showing an area of low Mn, (pale) and the high and variable levels
of melanin in the lower half. (C) A track through the heavily pigmented region,
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very low in melanin (designated herein as amelanotic/low).
Fig. 15(B) is a bioinformatic generated image that shows the
melanin content more clearly. Fig. 15(C) illustrates high-resolution
pathology tracks through the heavily pigmented region while
Fig. 15(D) shows tracks through the amelanotic region.
There is a large difference in Mn content between the
pigmented and amelanotic areas of this tumour, (B30 000 ncps
versus B3000 ncps, respectively) with some pigmented areas
exceeding 100 000 ncps. Approximately 50% of this tumour
section has Mn values with a median of 3000 ncps.
The clinical implications of this heterogeneity for radiation
treatment are as follows. If such a tumour were to be irradiated,
we would expect that most of the amelanotic cells would be
killed or be sufficiently damaged so as to be unable to undergo
further division. The remaining radioresistant cells would
repair their damage and the cancer would have a probability
of B0.5 of progressing (depending on where subsequent clinical
data reveal the most appropriate Mn threshold(s) to be set). The
above two examples of breast and melanoma tumours reflect the
importance of spatial information derived via LA-ICP-MS, where
adequate sampling of different tissue sections will generate the 3D
composition of a tumour. Since a tumour will usually also contain
infiltrating immune cells, areas of blood, necrosis, fibrosis and cells
undergoing apoptosis, it is necessary to take into consideration the
proportion of cancer cells, and their Mn contents, in relation to
each of these various populations to determine the probability of
tumour reoccurrence after radiation treatment.
As illustrated by the above examples, tumours are rarely
homogeneous. Cancer cells and stromal cells in a tumour are
interacting dependent systems, as shown in prostate cancer cells
that have metastasised to bone and are dependent upon osteoblasts
in that niche to survive.57 It is for this reason that while homo-
geneous tissue culture cell populations are useful for research
purposes, they rarely provide prognostic clinical information of
relevance to a specific patient. The lack of supporting stromal cells
in tissue culture and the supply of nutrients and metals is quite
unlike the supply from the harsh local environment of a tumour
with its acidic and anoxic areas and the dysregulated access of
metals and nutrients from a compromised vasculature.
We conclude from the above data that (i), within-tumour
heterogeneity of Mn levels is one of the most critical issues that
needs to be considered in the appropriate planning of radiotherapy.
Furthermore, given the variation in amount and distribution of the
stromal and cancerous components of a tumour, it is apparent
that (ii), homogenising tumour samples to generate predictive
biomarkers, will destroy, (or certainly compromise), the spatial
information which is of utmost clinical importance. In this
context, regions of high Mn content that are likely to survive
radiation treatment, are a critical component of the information
required to make prudent decisions on radiation dosages and
the probability of tumour reoccurrence.
Discussion
The LA-ICP-MS data on the seven different types of cancers together
with the published data on clinically-inferred radioresistance,
patient survival and the published non-enzymatic catalytic chemistry
of Mn interactions, are all consistent with a Mn-complexes/ROS
scavenging/tumour radioresistance hypothesis.
The Mn-based data from these 7 cancer types highlight the
major outcome of this study: measurements of Mn levels and
their distribution in these tumour types may provide a clinically
useful quantitative readout of the probability of radioresponsiveness
of a particular tumour and the probability of its reoccurrence in that
patient. The implications of these data may be more general. If
LA-ICP-MS analyses of other tumour types also support these
conclusions, then Mn-based diagnostics may turn out to be a
useful pan-oncological metabolic marker in clinical radiotherapy.
It is clear that some clinicians and researchers firmly believe
that the radioresistance of tumours is a property of up-regulated
enzymatic DNA repair systems, up-regulated enzymatic networks
involving ROS scavenging by superoxide dismutases, catalases
and peroxidases, and/or mutations in genes that lead to altered
proteins that confer radioresistance in tumours.
In this Discussion, we examine the relevant data bearing on
these beliefs and contrast the evidence with Mn-based non-
enzymatic metabolic systems that are held to underpin the data
from the 7 cancer types examined herein.
DNA repair and radioresistance?
As regards the proposed primacy of enhanced enzymatic DNA
repair after radiation treatment, there is a straightforward and
testable prediction. Do cells up-regulate genes involved in
repairing double-strand breaks, pyrimidine dimers, single-strand
breaks, base damage and DNA crosslinks after radiation treatment?
Some answers are available from both tissue culture systems
and patient samples. Large scale gene expression analyses on
microarrays from the National Cancer Institute’s set of 60
cancer cell lines, (which are derivatives of lung, melanoma,
prostate, breast, colon, ovary, kidney and leukemic cells) were
performed on these cell lines after ionizing radiation. Only 18 genes
exhibited significantly increased expression that distinguished cell
lines with a degree of radioresistance, from other cell lines, but
these upregulated genes were not enriched for DNA repair genes.58
Gene expression analyses on irradiated breast, prostate and
gliosarcoma cells also revealed that upregulated genes were not
enriched for DNA repair. Furthermore, genes upregulated in tissue
culture were a different group from those that were upregulated
when the same prostate cancer cell line was grown as a solid
tumour and irradiated in athymic nude mice.59 In vivo up regulation
also did not enrich for DNA repair.
There are now more than 177 human genes known to be
involved in DNA repair,60 however, only a handful of these are
upregulated in tumours following radiation treatment.61,62
In addition, only fragmentary reports exist on systematically
connecting any upregulation of repair genes to clinically-inferred
radioresistance across a diverse suite of cancer types at the same
time (such as those investigated herein). Studies have generally
been restricted to the in-depth examination of DNA variants in
single genes such as BRCA2, in specific cancer types. What has yet
to be demonstrated is the spatial transcriptomics of repair genes in
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In irradiated yeast cultures, ‘‘few if any of the genes involved
in repairing DNA lesions produced in this study, including
double-strand breaks, pyrimidine dimers, single-strand breaks,
base damage and DNA crosslinks are induced in response to
toxic doses of the agents that produce these lesions’’.63
It needs to be emphasised that upregulation of a single gene
rarely alters phenotype, biochemical or otherwise. It takes a
coordinated network of repair enzymes to carry out DNA repair
and increasing the level of a single network component is rarely
productive if other members of the network remain at normal
levels. The reason is that it is the flux through the network that
is critical, and an upregulated single component usually leaves
the output largely unchanged. Except for a dozen or so genes
that render patients extremely radiosensitive when they are
mutated in the germ line, the genome-centric upregulated
input for tumour radioresistance remains weak.
In in vitro settings and bacterial studies, the consequences
of radiation treatment leave little room for ambiguity. Large
experimental data sets all lead to the same outcome: it is the
efficient protection of the proteome from ROS, not protection
of DNA, that underpins radioresistance. It is undamaged
proteins that play the major role in radioresistance.12,14–17,64
Protecting these proteins, including those involved in DNA
repair, is largely via non-enzymatic Mn-complexes, via the
antioxidant properties of the so called high symmetry (H-Mn2+)
complexes.19
We conclude that we cannot formally eliminate the possibility
that the upregulation of human genes involved in DNA repair is
the dominant variable that accounts for the very different radio-
resistance and patient survival data of the seven tumour types.
However, until the 2D spatial transcriptomic data of human
DNA repair genes on tissue samples become available, (using
technologies such as tissue sections positioned on arrayed
reverse transcription primers65), the clinical value of upregulated
DNA repair systems remains moot.
Enzyme-based radioresistance?
An additional contribution to radioresistance could arise from
the increased activity of superoxide dismutases (CuZnSOD and
MnSOD), catalases and peroxidases. In this context, it needs to
be noted that B90% of the enzymatic superoxide dismutase
activity normally stems from CuZnSOD, with MnSOD making a
contribution of only B10%. MnSOD is restricted to mitochondria
and cannot scavenge ROS in the nucleus, while CuZnSOD is active
in both the cytoplasm and the nucleus and is not so restricted.
Whole organismal data revealed that when human CuZnSOD
and human catalase were upregulated in transgenic mice and
those mice given 10 Gy whole body radiation, there were no
significant survival differences between mice that upregulated
both CuZnSOD and catalase relative to controls.66
When the enzymatic activities of Cu/ZnSOD and MnSOD
were compared using classical enzymological assays in homogenized
cancer samples in a wide range of tumours, no correlation
emerged between these enzymatic activities and clinically-inferred
radioresistance.67 Second, examination of human mesothelioma
biopsies for MnSOD by immunostaining of patient samples
revealed no significant association between MnSOD levels and
patient survival.68 Third, assays for CuZnSOD, MnSOD, catalase
and glutathione peroxidase in 31 different human cancer cell
lines revealed that none of their activities were associated with
resistance towards ionizing radiation.69,70 Other examples from
the large literature on superoxide dismutases, mainly in genetically
engineered cell lines, demonstrate that increasing MnSOD gene
dosage does lead to increased radioresistance in experimentally
manipulated systems.71,72 In human tissue samples, there can be a
decrease in both CuZnSOD and MnSOD, an increase in MnSOD,
no difference in CuZnSOD, or decreases in catalase.73–75 Crucially,
what is yet to be demonstrated is the 2D spatial enzymology of
CuZnSOD, MnSOD, catalases and peroxidases in tissue sections
across a diverse range of clinical samples.
We conclude that we cannot formally eliminate the possibility
that the upregulation of these enzymatic scavengers of ROS is the
dominant variable that accounts for the very different radio-
resistance and patient survival data of the seven tumour types.
Once again, until the spatial enzymology on human tissue
samples becomes available, the clinical significance of the
upregulation of enzymatic scavengers of ROS, while unlikely,
cannot be discounted.
Non-enzymatic ROS scavengers and radioresistance?
The LA-ICP-MS data revealed that Mn was the distinguishing
metal in its association with clinically-inferred radioresistance
and patient survival, while Cu, Zn and Fe revealed no consistent
associations. This primacy of Mn was a consistent finding. One
can ask therefore whether the clinically-inferred radioprotective
effects of high Mn levels in our LA-ICP-MS data have a parallel
in systems that allow the fundamental principles of metallomic
interactions to be evaluated under conditions where input
variables are strictly controlled. One such platform is in vitro
radiochemistry: the irradiation of purified proteins in defined
buffers together with combinations of small molecules and
metals. This allows precise measurements of the efficacy of
different antioxidant complexes against damaging ROS.
Some of these parallels to the LA-ICP-MS data, although
distant, are striking in their revelation of fundamentally conserved
principles. When glutamine synthetase (GS) was irradiated in
phosphate buffer alone it suffered considerable damage from
ROS, with recoverable enzymatic activity being 50% at 100 Gy.13
The addition of Mn2+ and a nucleoside protected against protein
damage: 50% enzymatic activity was now retained at 10 000 Gy.
In this particular case, it was the spontaneous formation of the
triple complex, Mn2+-uridine-orthophosphate, that was the key
radioprotectant. Under these same conditions, there were no
protective effects of note with Cu2+, Zn2+ or Fe2+.13
Antioxidant activities have also been measured in a different
in vitro chemical system, namely that of metal-drug complexes.
For example, mefenamic acid is a nonsteroidal anti-inflammatory
drug which acts as a free radical scavenger and its properties
are enhanced when it is complexed with various metals. It is
the mefenamic acid complex with Mn that has the highest
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Radioprotective supremacy: Mn-peptide complexes
The most potent antioxidant Mn2+-complexes found to date
are those in combination with peptides.13 Thus, a particular
decapeptide in potassium phosphate or sodium bicarbonate
buffer with Mn2+, protects glutamine synthetase activity even
more strongly than Mn2+-complexes with nucleosides, with
50% activity retained at B50 000 Gy. Decapeptides are readily
taken up by cells in tissue culture and in mice, and one such
tripartite Mn2+-peptide-orthophosphate complex is the most
effective radioprotectant so far known. Not only is the survival
of irradiated cells in culture massively increased, but so also is
the survival of mice given whole body radiation.18
The existence of radioprotective Mn2+-complexes with peptides
has significant implications for tumour radiotherapeutics. Tumours
have anoxic/hypoxic regions and areas of cell death where there
is no shortage of dying cells and their autoproteolytic digests.
This is evident in the large necrotic areas of many tumours,
such as glioblastomas (for example, in Fig. 3). In such an
environment of cell death and of variation-selection processes,
the surviving cells have access to an increased supply of
metabolites including peptides, phosphates, nucleosides, free
amino acids and all manner of metabolites. Thus, it only
requires uptake of Mn from the bloodstream to automatically
produce non-enzymatic, ROS-scavenging, complexes. The
equilibrium of complex formation is greatly in their favour,
with metabolites in the millimolar range and Mn in the
micromolar range.
Depending on the level of Mn in the bloodstream and the
levels of Mn transporters in tumour cells, some tumours will
unavoidably accumulate more Mn than others. Different cells
within a tumour, as well as tumours in different individuals,
will have different concentrations of Mn2+-complexes with
different metabolites.
The results of this natural sequence of molecular events are
seen in the context of Mn uptake in normal tissues and organs
and their cancerous derivatives.
Mn uptake and its distribution in normal tissues/organs
Under normal conditions, nearly all Mn enters the human body
from the gastrointestinal tract via the hepatic portal vein and is
taken up by the liver, while excess Mn is exported via the bile
duct into the small intestine. This dual system controls Mn
levels in the blood via the influx and efflux metal transporters
in the liver and bile duct epithelium: predominantly via
SLC39A14 (Mn uptake by the liver) and SLC30A10 (Mn efflux
via the bile duct epithelium).23,24 If these transporters are
altered by mutation, allelic variants, or regulatory elements,
the level of Mn in the blood is changed. When this occurs,
dietary Mn uptake by the liver is reduced, more Mn is directed
into the blood, and higher than normal concentrations accumulate
in organs such as the brain.
We found that Mn levels were highest in normal liver and
pancreas but lower in cardiac muscle, cerebral cortex and
spleen (ESI,† Table S3). These levels agree with other methods,
reinforcing the finding that Mn content in tissue sections
measured via LA-ICP-MS is a reflection of in vivo content, and
not an artefact of fixation or metal loss. Importantly, ESI,†
Table S3 illustrates the Mn content in organs of three healthy
individuals, #341, #342 and #333 where two different anatomical
regions have been sampled from the same individual and hence
are in the same genetic background. These data provide an initial
insight into LA-ICP-MS determined Mn levels between different
normal tissues and organs in healthy individuals.
Mn uptake and its distribution in tumours
The quantities of Mn that are released into the bloodstream are
directly consequential to the uptake of Mn by tumours, irrespective
of whether the tumours are primary or distant metastases (as
revealed in Fig. 6 with primary and metastatic melanomas). Mn
levels will depend on blood supply to the tumour, access to, and
leakiness of the tumour vasculature, and the expression levels
of the influx/efflux transporters in cells in different parts of the
tumour.
While the normal liver and normal bile duct Mn transporters
are products of normal genomic balance, nearly all solid tumours
have grossly reorganised genomes carrying amplifications, deletions,
inversions, translocations and epigenetic modifications. They
are aneuploid and segmentally aneuploid. This has significant
ramifications for radioresistance of tumours. For example, the
determinant of how much Mn is available to cells within a
tumour, (both cancerous and stromal cells) is first dependent
upon how much Mn has been released into the bloodstream.
This will depend on the allelic variants in the transporters of
that specific individual and the dietary intake of Mn for that
individual.
The level of Mn in a tumour thus depends on the extent to
which the transporter genes are amplified, deleted or dysregulated,
resulting in over- or under-expression of their transporter proteins.
Owing to the truly massive genomic reorganization in most
tumour cells, it is unavoidable that influx and efflux transporters
will vary in copy number (from being homozygously deleted to
multiple copies; 0, 1, 2, 3, 4, etc.) in different tumour cells. This will
result in different Mn influxes and effluxes in different cells in a
tumour.
In summary, each individual will have a certain amount of
Mn entering the bloodstream which is available for tumour
uptake. Depending on the expression level of influx and efflux
transporters in that tumour, at that time, a particular level of
Mn is reached as a result of natural biochemical processes. It is
merely extraction efficiency from the blood, and retention
within tumours, that are the underlying forces.
We conclude that this non-enzymatic antioxidant system
based on Mn2+-complexes arises naturally, and proceeds inexorably,
as a result of the liver/biliary gateway and the dietary supply of Mn2+.
It leads to variation in the levels of Mn2+-complexes in different
tumours and provides a pre-loaded system for ameliorating damage
from ROS. When a tumour is irradiated, this frontline cellular
defence and cleaning system is instantaneously available for
protection of the proteome unlike the time delay for the
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Conclusions and future implications
Given the above data from LA-ICP-MS, from DNA repair, from
enzymological scavenging and from non-enzymatic Mn-based
antioxidant systems, the Mn-complexes/ROS scavenging/tumour
radioresistance hypothesis is currently the most plausible. It
provides an intellectual framework in radiation tumour biology
of the type sought by Gatenby4 and is testable via randomised
clinical trials or initially by sequential testing of patients of any
tumour type for whom radiation treatment is the appropriate
option.
To facilitate a practical clinical connection, we outline an
LA-ICP-MS strategy using the metallomic and molecular carto-
graphy of tumours that may be helpful. This is placed into
context with current radiation regimens that largely treat
cancer patients within a single tumour type as a near uniform
homogeneous cohort.
The final goals: beyond the one-size-fits-all approach to patient
treatment
The current situation in radiation treatment of a patient is
exemplified by adjuvant radiotherapy for breast cancer in the
UK and the USA. In the UK a standardised protocol of 50 Gy is
delivered in 25 fractions of 2 Gy each over a period of 5 weeks
while in the USA it similar: 40 Gy in 15 fractions, or 42.5 Gy in
16 fractions.77,78 Standardised protocols are the norm for other
cancers, with each tumour category having its own specific
dosages and fractions. The issue with such generic treatment,
as the LA-ICP-MS 2D spatial data have revealed, is that it does not
deal with the considerable heterogeneity within each tumour type.
If tumour radioresistance turns out to be predominantly
determined by Mn and the sizes of pools of metabolites,
then the first task is to generate a quantitative readout of the
probability of radioresistance of any tumour so that a physician
can tailor a suitable treatment that goes beyond the one-size-
fits-all approach (Fig. 16). Given that a single ablation track
across a 1 mm tumour section can be completed in B7 seconds,
regions of interest on a standard pathology slide can be analysed
in minutes to obtain an overview of tumour heterogeneity via
metallomic inhomogeneities. The second task is to determine the
threshold(s), below and above which the radiation dose can be so
adjusted so as to provide maximum killing power to the tumour,
and the minimum to nearby healthy tissues and organs. This can
be found empirically, either via conventional randomised clinical
trials, or by correlating patient outcomes in a single tumour type
where heterogeneity is extreme.
The foundation for both these tasks lies in the use of
Mn determinations and metal-labelled probes to generate a
multi-layered cartography of tumour tissue sections.
Multimodal cartography
Any molecular entity, be it antibody, nucleic acid, or drug, can
be tagged with different metals79,80 and hybridised to adjacent
human tissue sections so as to reveal their localised concentrations
relative to the positional coordinates of Mn. The power of Mn
maps is that they can be overlaid with other metal-based maps,
such as that of the distribution of drug targets, antibodies and
immune cells. The result is a multi-level cartographic output that
integrates potential radiation information with other clinically
significant modalities. These can include the distribution of the
ER, PR and HER2 receptors in breast cancer, cell division markers
such as Ki-67, immune system markers such as PD-1 and PD-L1 or
any of the currently ‘‘actionable drivers’’ of tumour progression
found from genomic analyses, such as mutated BRAF in melanoma.
These multi-layered maps can be integrated via automated
image scanning technology and machine learning algorithms
to provide clinically informative quantitative insights into the
global properties of that particular tumour. The rapid acquisition
of multiple features in routine pathological processing laboratories
using LA-ICP-MS instrumentation may help radiation oncologists
to better tailor the appropriate radiation dosage to individual
patients to increase overall survival.
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